Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

Summary

This study evaluates the rate of radiological disease progression with the new 2nd generation positron emission tomography (PET) radiopharmaceutical, 18F-DCFPyL, in patients with metastatic castration (mCRPC) and non-metastatic (nmCRPC) castration resistant prostate cancer who have evidence of biochemical (PSA) disease progression without evidence of radiological disease progression on conventional standard radiologic testing (99mTc-methylene diphosphonate bone scan and CT).

Timeline

Start

2019-10-01

Primary completion

2021-10-21

Completion

2021-10-21

Drugs

Indications